glp 1 and diabetic retinopathy Updated guidance from the PCDS ABCD: Managing the national GLP-1 RA shortage GLP-1/GIP Receptor Agonists and Diabetic
Description
this week
In conclusion, many patients receiving GLP-1RA suffer from Ozempic face and facial aging
Appetite changes
Further studies are needed to investigate the bone impact of GLP-1Ra, dual- and triple-receptor agonists for GLP-1, glucose-dependent insulin releasing polypeptide (GIP), and glucagon in PwO.
A recent study suggests that a GLP-1 drug, liraglutide, may protect the brains of people with mild Alzheimers disease, slowing cognitive decline by 18% over one year.
Take consistently for optimal results
